toxicities associated with rucaparib for the treatment of ovarian cancer
Published 7 years ago • 243 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
1:36
dr. coleman discusses the toxicities associated with rucaparib in patients with ovarian cancer
-
2:31
toxicities associated with parp inhibitors in ovarian cancer
-
2:36
managing toxicities in advanced ovarian cancer
-
5:11
defining rucaparib’s value in recurrent ovarian cancer
-
4:38
managing toxicities in ovarian cancer treatments
-
1:41
the clinical activity of rucaparib in patients with ovarian cancer
-
1:21
rucaparib may improve pfs in patients with ovarian cancer
-
1:11
solo3 highlights toxicities with olaparib in ovarian cancer
-
5:18
rucaparib for ovarian cancer
-
3:06
rucaparib maintenance therapy for high-risk ovarian cancer
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer
-
1:40
mcneish: rucaparib for treatment of ovarian cancer
-
2:58
rucaparib for relapsed ovarian cancer: safety profile
-
4:20
rucaparib explored for high-risk ovarian cancer
-
2:07
rucaparib in platinum-sensitive ovarian cancer
-
3:15
patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis
-
2:18
parp inhibition in recurrent ovarian cancer
-
1:56
parp inhibitor costs give patients with ovarian cancer financial toxicity
-
34:17
parp inhibitors for the treatment of ovarian cancer - gottfried konecny, md | uclamdchat